系统性审查研究比较infliximab和adalimumab在自身免疫性脑膜炎中的研究
Oliver Mase1, Mustafa Qasem2, Nicholas Beare3,4
1School of Medicine, University of Liverpool, Liverpool, UK.
BMJ open ophthalmology
|July 26, 2023
概括
阿达利穆马布 (ADA) 和因弗力西马布 (IFX) 对自身免疫性脑膜炎的有效性和安全性相似. 然而,需要更多高质量的研究,比如随机对照试验,来证实这些发现.
科学领域:
- 眼科医生 眼科 眼科
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
背景情况:
- 自身免疫性脑膜炎是一种严重的疾病,需要有效治疗.
- 抗瘤坏死因子药物,如阿达利穆马布和因弗利西马布,用于治疗.
- 在自身免疫性脑膜炎中对阿达利穆马布和因弗利西穆马布的直接比较是有限的.
研究的目的:
- 审查现有的有效性研究,比较阿达利穆马布和因弗力西马布用于自身免疫性脑膜炎.
- 评估两种药物的治疗反应和不良事件.
- 识别当前证据中的空白.
主要方法:
- 在PubMed,Scopus,Web of Science和谷歌学者 (2014-2022) 的系统文献搜索.
- 包括直接比较自免疫性脑膜炎中阿达利穆马布和因弗力西马布的初级研究.
- 专注于治疗有效性和不良事件发生率.
主要成果:
- 六项研究符合资格标准;所有研究都是观察性或回顾性.
- 观察到相似的有效性和副作用的形状是适合阿达利穆马布和因弗利西穆马布.
- 限制包括小样本大小,专注于贝塞特病和潜在偏差.
结论:
- 在自身免疫性脑膜炎的有效性和安全性方面,阿达利穆马布和因弗利西穆马布似乎是可比的.
- 目前的证据受到低质量和偏见高风险的限制.
- 大规模的随机对照试验是必要的,以确定最终的疗效和安全性.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
174
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
174
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195
Inflammatory Bowel Disease IV: Pharmacological Management
154
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
154
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
153
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
153
Inflammatory Bowel Disease II: Crohn's Disease
296
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
296


